Home » Clinical Trials » Solid tumors » NCT05795595
NCT05795595

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed or Refractory Solid Tumors

Study Summary

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.

Want to learn more about this trial?

Request More Info

Interventions

CTX131BIOLOGICAL
CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)

Study Locations

FacilityCityStateCountry
Research Site 3DuarteCaliforniaUnited States
Research Site 7ChicagoIllinoisUnited States
Research Site 6BostonMassachusettsUnited States
Research Site 2St LouisMissouriUnited States
Research Site 4DurhamNorth CarolinaUnited States
Research Site 1NashvilleTennesseeUnited States
Research Site 5HoustonTexasUnited States

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026